Endo, Impax Get DC Circuit to Dismiss FTC Case Over Opioids (2)

Endo Pharmaceuticals Inc. and Impax Laboratories LLC escaped the Federal Trade Commission’s appeal of a lawsuit alleging the companies’ agreement over the use of an extended-release painkiller violated antitrust law.

A panel of US Court of Appeals for the D.C. Circuit judges found Friday that the FTC failed to state a claim when it hit Endo and Impax with a lawsuit under sections 1 and 2 of the Sherman Act in January 2021. The judges agreed with the US District Court for the District of Columbia, which in March 2022 dismissed the case against the two companies and their corporate ...